GlassScriptPhysician profile
Tavis Dancik
NPI 1396971263
$4,161.59
in general payments reported to CMS, 2019-2025
30 companies · $69.22 in 2025
The $69.22 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $810 · 2020: $408 · 2021: $560 · 2022: $1,015 · 2023: $933 · 2024: $366 · 2025: $69.22.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,248 · Education: $120.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,247.80 |
| Education | $120.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $435.66 | 2020-2024 | Acthar |
| Aurinia Pharma U.S., INC. | $371.91 | 2021-2025 | Lupkynis |
| Mallinckrodt Enterprises LLC | $342.74 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $340.51 | 2019-2023 | Farxiga |
| Otsuka America Pharmaceutical, INC. | $283.30 | 2019-2023 | Jynarque |
| Amgen INC. | $209.06 | 2019-2024 | Krystexxa, Tavneos |
| Glaxosmithkline, LLC. | $191.29 | 2020-2023 | Benlysta |
| Alexion Pharmaceuticals, INC. | $176.66 | 2019-2024 | Ultomiris |
| Opko Pharmaceuticals, LLC | $168.27 | 2019-2024 | Rayaldee |
| Ani Pharmaceuticals, INC. | $167.60 | 2022-2024 | Purified Cortrophin Gel |
| Horizon Therapeutics Plc | $155.85 | 2020-2023 | Krystexxa |
| Travere Therapeutics, INC. | $155.46 | 2021-2025 | |
| Daiichi Sankyo INC. | $133.66 | 2020-2023 | Injectafer |
| Bayer Healthcare Pharmaceuticals INC. | $127.23 | 2022-2023 | |
| Calliditas Therapeutics US INC. | $109.93 | 2022-2023 | Tarpeyo |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $99.35 | 2020 | |
| Ablative Solutions, INC. | $86.97 | 2020 | |
| Vifor Pharma, INC. | $80.78 | 2019-2023 | Veltassa, Korsuva |
| Boehringer Ingelheim Pharmaceuticals, INC. | $68.52 | 2022-2025 | Jardiance |
| Ardelyx, INC. | $67.56 | 2024-2025 | Ibsrela |
| Akebia Therapeutics INC | $65.39 | 2019-2024 | Vafseo |
| Arbor Pharmaceuticals, INC. | $63.85 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $55.80 | 2020-2023 | Gattex |
| Amag Pharmaceuticals, INC. | $46.51 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $32.32 | 2019 | |
| Fresenius USA Marketing, INC. | $31.45 | 2019-2021 | |
| Ultragenyx Pharmaceutical INC. | $30.51 | 2021-2022 | |
| Lilly USA, LLC | $25.06 | 2024 | Jardiance |
| Novartis Pharmaceuticals Corporation | $22.43 | 2024 | |
| Shire North American Group INC | $15.96 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tavis Dancik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.